Hepion up as NASH drug study gets safety board's nod to proceed

Hepion Pharmaceuticals

15/06/2023 16:14

** Shares of Hepion Pharmaceuticals Inc  HEPA.O  up 2% at
$11.71
    ** Drug developer says the Data and Safety Monitoring Board
(DSMB) has given clearance to co's mid-stage NASH study to
proceed without modification, after review of current data 
    ** Trial is evaluating safety and efficacy of co's drug
candidate rencofilstat in 336 subjects with nonalcoholic
steatohepatitis (NASH) or fatty liver disease
    ** DSMB is an independent group of experts who must monitor
multisite clinical trials involving interventions that pose a
potential risk to the participants - NIH
    ** On track to complete enrollment in Q1 2024- HEPA
    ** Stock up 96% YTD

 (Reporting by Aditya Samal)
 ((Aditya.Samal@thomsonreuters.com;))